Cingulate Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cingulate Inc. (CING) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $45.24 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$1.26M.
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $1.30M.
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.31M, a 30.94% increase year-over-year.
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.09M.
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $1.47M.
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$4.54M, a 187.43% decline from fiscal 2023.
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $5.19M, a 556.59% increase from fiscal 2022.
- Cingulate Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $791.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $45.24K 10-Q · filed 2026-08-13 | $1.36M derived: sum of 3 quarters · filed 2026-08-13 | $2.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-14 | $2.62M derived: sum of 2 quarters · filed 2026-05-14 | $3.71M derived: sum of 3 quarters · filed 2026-05-14 | $3.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.40M derived: sum of 2 quarters · filed 2026-03-18 | $2.32M derived: sum of 3 quarters · filed 2026-08-13 | $1.47M 10-K · filed 2026-03-18 |
| 2025-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.01M derived: sum of 2 quarters · filed 2026-08-13 | $156.49K 10-Q · filed 2025-11-13 | $1.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$82.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$935.27K 10-Q · filed 2026-08-13 | $66.27K derived: sum of 3 quarters · filed 2026-08-13 | -$338.06K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$852.91K 10-Q · filed 2026-05-14 | $148.62K derived: sum of 2 quarters · filed 2026-05-14 | -$255.71K derived: sum of 3 quarters · filed 2026-05-14 | -$398.60K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $597.21K derived: sum of 2 quarters · filed 2026-03-18 | $454.32K derived: sum of 3 quarters · filed 2026-03-18 | -$4.54M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$404.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$547.22K derived: sum of 2 quarters · filed 2025-11-13 | -$5.54M 10-Q · filed 2025-11-13 | -$1.87M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$142.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | -$5.14M 10-Q · filed 2025-08-19 | -$1.46M derived: sum of 3 quarters · filed 2025-08-19 | -$917.79K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | -$5.00M 10-Q · filed 2025-05-08 | -$1.32M derived: sum of 2 quarters · filed 2025-05-08 | -$774.90K derived: sum of 3 quarters · filed 2025-05-08 | $557.37K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $4.22M derived: sum of 2 quarters · filed 2025-03-27 | $5.55M derived: sum of 3 quarters · filed 2025-03-27 | $5.19M 10-K · filed 2025-03-27 |
| 2023-09-30 | $544.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.88M derived: sum of 2 quarters · filed 2024-11-07 | $1.52M 10-Q · filed 2024-11-07 | $2.11M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $973.49K 10-Q · filed 2024-08-13 | $1.57M derived: sum of 3 quarters · filed 2024-08-13 | $2.04M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$358.78K 10-Q · filed 2024-05-08 | $234.77K derived: sum of 2 quarters · filed 2024-05-08 | $704.38K derived: sum of 3 quarters · filed 2024-05-08 | -$14.15K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $593.54K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.06M derived: sum of 2 quarters · filed 2024-04-01 | $344.63K derived: sum of 3 quarters · filed 2024-04-01 | $791.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $469.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$248.91K derived: sum of 2 quarters · filed 2023-11-13 | $197.46K 10-Q · filed 2023-11-13 | -$3.21M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$718.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$272.15K 10-Q · filed 2023-08-14 | -$3.68M derived: sum of 3 quarters · filed 2023-08-14 | -$2.14M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $446.37K 10-Q · filed 2023-05-10 | -$2.96M derived: sum of 2 quarters · filed 2023-05-10 | -$1.42M derived: sum of 3 quarters · filed 2023-05-10 | -$620.62K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$1.87M derived: sum of 2 quarters · filed 2023-03-10 | -$1.07M derived: sum of 3 quarters · filed 2023-03-10 | -$1.32M 10-K · filed 2023-03-10 |
| 2021-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.34M derived: sum of 2 quarters · filed 2022-11-14 | $2.08M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $799.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $541.67K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$257.69K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$448.81K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |